Clinical Trials Logo

Pulmonary Arterial Hypertension clinical trials

View clinical trials related to Pulmonary Arterial Hypertension.

Filter by:

NCT ID: NCT03810443 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension

HYPER2
Start date: January 14, 2019
Phase: N/A
Study type: Interventional

Dyspnea is a major symptom in pulmonary arterial hypertension and people with the same haemodynamic have generally different degree of dyspnea in pulmonary arterial hypertension. The hyperventilation syndrome is a frequent cause of dyspnea in general population and in respiratory diseases like asthma but has never been studied in pulmonary hypertension. The goal of this study is to measure the prevalence of pulmonary hypertension in a population of patients with controlled pulmonary arterial hypertension (PAH).

NCT ID: NCT03795428 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Long-Term Extension Study of PB1046 in PAH Subjects Having Completed Studies PB1046-PT-CL-0004 or PB1046-PT-CL-0005

LTE
Start date: January 15, 2019
Phase: Phase 2
Study type: Interventional

This is a multi-center, Phase 2 Long-Term Extension Study to assess the safety, tolerability, and efficacy of PB1046 at an optimally titrated dose. This is a Long-Term Extension Study for subjects with pulmonary arterial hypertension (PAH), having participated in double-blind Study PB1046-PT-CL-0004 or open-label Study PB1046-PT-CL-0005. The study will include adult subjects previously diagnosed with symptomatic PAH, who are receiving background clinician-directed therapy for PAH. All subjects during the Long-Term Dosing and Safety Follow-Up Period, will continue to be followed for safety and tolerability, as well as for periodic efficacy, quality of life data and immunogenicity. The study will continue until such time when PB1046 becomes commercially available to the subject or the Sponsor terminates the study due to lack of efficacy, safety or other reasons.

NCT ID: NCT03789643 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension

RELIEF-PAH
Start date: March 2019
Phase: Phase 2
Study type: Interventional

Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-251 administered for 24 weeks in participants with pulmonary arterial hypertension (PAH)

NCT ID: NCT03782818 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Olaparib for PAH: a Multicenter Clinical Trial

Start date: March 15, 2019
Phase: Phase 1
Study type: Interventional

The main OBJECTIVE of this proposal is to extend our preclinical findings on the role of DNA damage and poly(ADP-ribose) polymerases (PARP) inhibition as a therapy for a devastating disease, pulmonary arterial hypertension (PAH), to early-phase clinical trials. We, and others, have published strong evidence that DNA damage accounts for disease progression in PAH and showed that PARP1 inhibition can reverse PAH in several animal models1. Interestingly, PARP1 inhibition is also cardioprotective. Olaparib, an orally available PARP1 inhibitor, can reverse cancer growth in animals and humans with a good safety profile, and is now approved for the treatment of ovarian cancer in Canada, Europe and the USA. The time is thus right to translate our findings in human PAH. The primary objective of this Phase 1B study is to confirm the safety of using olaparib in PAH patients, and precise the sample size of a future Phase 2 trial. In addition to safety, efficacy signals will thus be assessed.

NCT ID: NCT03744637 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

A Study of Single Doses of MK -5475 on Pulmonary Vascular Resistance (MK-5475-002)

Start date: January 14, 2019
Phase: Phase 1
Study type: Interventional

This is a 2-part, 2-panel study of MK-5475 in participants with Group 1 pulmonary arterial hypertension (PAH). Part 1 is a double-blind, randomized, single-ascending dose assessment of the safety, tolerability and pharmacokinetics (PK) of inhaled MK-5475. Part 2 of this study is an open-label study and will assess the safety, tolerability, PK and pharmacodynamics of inhaled MK-5475 at dose determined by results of Part 1 of the study. There is no formal hypothesis to be tested.

NCT ID: NCT03738150 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension

SPECTRA
Start date: February 2019
Phase: Phase 2
Study type: Interventional

This study evaluates the effect of sotatercept (ACE-011) in adults with Pulmonary Arterial Hypertension. Each eligible participant will receive standard of care (SOC) plus sotatercept (ACE-011) for a 24 week treatment period followed by a 16 week follow up period.

NCT ID: NCT03718780 Not yet recruiting - Healthy Clinical Trials

Assessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During Exercise

TEASE
Start date: October 20, 2018
Phase: N/A
Study type: Interventional

The study aim is to monitor, during exercise tests carried out in various conditions, the alveolar dead space, by means of continuous transcutaneous measurement of Pt CO2, which would be used as a surrogate for arterial PaCO2. Validity of this measurement needs to be assessed against arterial sampling (either arterial, or arterialized capillary), especially with regards to the lag time required by the CO2 diffusion from the arterial compartment (PaCO2) to the cutaneous one (PtCO2), in particular when rapid changes of CO2 might be induced by exercise. The evaluation will be done in 2 different settings: - intensive care patients, equipped, for their routine clinical care, with an arterial line; this allows for a precise timed comparison between PaCO2 and PtCO2 readouts; - routine exercise test, where blood gas evaluation is done essentially by means of arterialized earlobe capillary sampling. Following assessment of validity of the measurement (and the lag time PaCO2-PtCO2 which might be necessary to introduce as a correction), evolution of dead space during excise test will be tested in different conditions: Healthy subjects, patients with Chronic Obstructive Pulmonary Disease (COPD), chronic heart failure (CHF), hyperventilation, Pulmonary artery hypertension (PAH), or interstitial lung disease (ILD)

NCT ID: NCT03708146 Recruiting - Clinical trials for Pulmonary Arterial Hypertension

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058

Start date: June 24, 2018
Phase: Phase 1
Study type: Interventional

This is a single centre, double-blind, randomised, placebo-controlled, parallel staggered group study of BIA 5-1058 in 10 different cohorts of 15 healthy subjects. Subjects will be randomly assigned to receive once-daily oral doses of BIA 5-1058 or matching placebo for 10 days. The primary objectives of the study are to assess the safety and tolerability of BIA 5-1058 after repeated ascending doses under fed and fasted conditions and to assess the pharmacokinetics (PK) of BIA 5-1058 after repeated ascending doses under fed conditions having matching fasting cohorts for comparison of bioavailability. It is planned that comparison cohorts will be dosed in parallel, i.e. Cohorts 1 and 2, 3 and 4, 5 and 6, 7 and 8 and 9 and 10. Cohorts may be split or dosed sequentially for logistical purposes; however, data from both comparison cohorts (e.g. Cohorts 1 and 2) must be available before dose escalation to the next dose levels.

NCT ID: NCT03688698 Completed - Clinical trials for Pulmonary Arterial Hypertension

PET/MRI in PAH Patients

Start date: May 1, 2016
Phase:
Study type: Observational [Patient Registry]

Aim of the study is to compare novel parameters of right ventricle (RV) function from right heart catheterization (RHC) and magnetic resonance imaging (MRI) with PET-derived RV FDG uptake.

NCT ID: NCT03683186 Enrolling by invitation - Hypertension Clinical Trials

A Study Evaluating the Long-Term Safety and Efficacy of Ralinepag in Subjects With PAH Via an Open-Label Extension

Start date: September 2018
Phase: Phase 3
Study type: Interventional

Study APD811-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.